All-Around R&D Process Based-on Functional Diagnosis
Compared to the traditional R&D roadmap that utilizing genetic engineered/commercialized cell lines for in vitro assay, and cell-derived xenografts (CDXs) for in vivo efficacy, LIDE proposes a R&D new roadmap upon Functional Diagnosis. Cells generated from either conditional reprogramming (CRCs) or fresh tumor tissues direct from patients can be used for primary screening. MiniPDX could be a secondary screening cascade to optimize the best candidate from a handful of molecules in a cost-effective manner, followed by traditional PDX for candidate determination. MiniPDX mouse trial and K-cell based RNAseq+FGI/whole exon sequencing would be a powerful platform for potential indication selection and patient stratification, which is highly recommended to be launched after candidate nomination and initiation of PCC stage.